CompaniesPalladio Biosciences

Palladio Biosciences

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (5)
View all

Total Trials

5

As Lead Sponsor

5

As Collaborator

0

Total Enrollment

51

By Phase

PHASE3: 3PHASE2: 1

By Status

TERMINATED: 3COMPLETED: 1NO_LONGER_AVAILABLE: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
Today
NCT03487913
NCT04152837
Hover over trial bars to see details

Recent Trials

NCT05208866Lead Sponsor
Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303
PHASE3Terminated
1 participants
Started: Feb 10, 2022 · Completed: Jul 29, 2022
NCT04064346Lead Sponsor
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
PHASE3Terminated
12 participants
Started: Oct 28, 2021 · Completed: Aug 3, 2022
NCT04152837Lead Sponsor
Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
PHASE3Terminated
7 participants
Started: Sep 2, 2020 · Completed: Jul 29, 2022
NCT03487913Lead Sponsor
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
PHASE2Completed
31 participants
Started: Sep 14, 2018 · Completed: Feb 11, 2020
NCT03717181Lead Sponsor
Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease
N/ANO_LONGER_AVAILABLE
Funding History (1)
D
Oct 7, 2020
Filing